Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

Customized drug discovery offers integrated target-to-lead and target-to-clinic ready small molecules

WILM­ING­TON, Mass. & BOSTON – (BUSI­NESS WIRE) – Charles Riv­er Lab­o­ra­to­ries Inter­na­tion­al, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched Log­i­caTM, an arti­fi­cial intel­li­gence (AI) pow­ered drug solu­tion that direct­ly trans­lates clients’ bio­log­i­cal insights into opti­mized pre­clin­i­cal assets. Log­i­ca lever­ages Valo’s AI-pow­ered Opal Com­pu­ta­tion­al Plat­form and Charles River’s lead­ing pre­clin­i­cal exper­tise, pro­vid­ing clients with trans­formed drug dis­cov­ery with a sin­gle inte­grat­ed offer­ing seam­less­ly trans­lat­ing tar­gets to can­di­date nomination.

Through our part­ner­ship with Valo, we’re inte­grat­ing Charles River’s lab­o­ra­to­ry capa­bil­i­ties with indus­try-alter­ing AI-dri­ven mol­e­c­u­lar design to pro­vide our clients with high­ly advance­able leads and can­di­dates, while tying client costs to val­ue gen­er­a­tion,” said Bir­git Gir­shick, Cor­po­rate Exec­u­tive Vice Pres­i­dent & Chief Oper­at­ing Offi­cer, Charles Riv­er. AI-pow­ered solu­tions are dri­ving drug dis­cov­ery for­ward and this is the kind of inno­va­tion our indus­try needs to ulti­mate­ly bring effec­tive treat­ments to patients faster.”

Valo is thrilled to part­ner with Charles Riv­er on this first of its kind offer­ing,” added David Berry, MD, Ph.D., founder, and CEO of Valo. We are cre­at­ing an oppor­tu­ni­ty to ful­ly out­source small mol­e­cule dis­cov­ery while pro­vid­ing a true risk-shar­ing mod­el with advance­able leads and can­di­dates with the goal of help­ing com­pa­nies scale faster, trans­lat­ing more bio­log­i­cal insight into can­di­dates to make bet­ter drugs for patients, faster.”

Logica’s Advance­able Lead (Log­i­ca-AL™) and Can­di­date (Logica‑C™) pro­grams, which are avail­able exclu­sive­ly from Charles Riv­er, are part of a mul­ti-year strate­gic part­ner­ship that Charles Riv­er and Valo announced ear­li­er this year. Log­i­ca-AL aims to pro­vide cus­tomers with high­ly advance­able, potent series with desired char­ac­ter­is­tics, such as in vit­ro absorp­tion, dis­tri­b­u­tion, metab­o­lism, and excre­tion (ADME) and selec­tiv­i­ty pro­files under­stood. In addi­tion, the Logica‑C offer­ing will use the advance­able leads and trained pre­dic­tive mod­els to rapid­ly progress the pro­gram, ulti­mate­ly aim­ing to deliv­er a devel­op­ment can­di­date that has under­gone nec­es­sary safe­ty and effi­ca­cy tests and is ready for IND-enabling studies.

Log­i­ca uti­lizes indus­try-lead­ing pre­dic­tive mod­els, chem­i­cal design and syn­the­sis capa­bil­i­ties, DNA-encod­ed libraries, in sil­i­co high through­put screen­ing from Valo’s Opal Com­pu­ta­tion­al Plat­form as well as Charles River’s lead­ing capa­bil­i­ties in all aspects of dis­cov­ery opti­miza­tion includ­ing high through­put screen­ing, med­i­c­i­nal chem­istry, ADME, biol­o­gy, phar­ma­col­o­gy, and ulti­mate­ly safe­ty test­ing and IND sub­mis­sion, join­ing togeth­er for the first time to cre­ate a com­pu­ta­tion-pow­ered, uni­fied tar­get-to-can­di­date offer­ing. Log­i­ca com­bines approach­es that have a demon­strat­ed abil­i­ty to pro­duce an advance­able lead series 90 per­cent of the time and deliv­er devel­op­ment can­di­dates 58 per­cent of the time. The prod­ucts will be offered with most of the client cost tied to success.

About Valo Health
Valo Health, Inc (“Valo”) is a tech­nol­o­gy com­pa­ny built to trans­form the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence (“AI”) com­pu­ta­tion. As a dig­i­tal­ly native com­pa­ny, Valo aims to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life­cy­cle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing the cost, time, and fail­ure rate. The company’s Opal Com­pu­ta­tion­al Plat­form™ con­sists of an inte­grat­ed set of capa­bil­i­ties designed to trans­form data into valu­able insights that may accel­er­ate dis­cov­er­ies and enable Valo to advance a robust pipeline of pro­grams across car­dio­vas­cu­lar meta­bol­ic renal, oncol­o­gy, and neu­rode­gen­er­a­tive dis­ease. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo also has offices in Lex­ing­ton, MA, New York, NY, San Fran­cis­co, CA, and Bran­ford, CT. To learn more, vis­it www​.val​o​health​.com.

About Charles Riv­er
Charles Riv­er pro­vides essen­tial prod­ucts and ser­vices to help phar­ma­ceu­ti­cal and biotech­nol­o­gy com­pa­nies, gov­ern­ment agen­cies and lead­ing aca­d­e­m­ic insti­tu­tions around the globe accel­er­ate their research and drug devel­op­ment efforts. Our ded­i­cat­ed employ­ees are focused on pro­vid­ing clients with exact­ly what they need to improve and expe­dite the dis­cov­ery, ear­ly-stage devel­op­ment and safe man­u­fac­ture of new ther­a­pies for the patients who need them. To learn more about our unique port­fo­lio and breadth of ser­vices, vis­it www​.criv​er​.com.


Charles Riv­er Investor:
Todd Spencer
Cor­po­rate Vice Pres­i­dent, Investor Rela­tions
+1- 7812226455

Charles Riv­er Media:
Amy Cian­cia­ru­so
Cor­po­rate Vice Pres­i­dent & Chief Com­mu­ni­ca­tions Offi­cer
+1 – 781-2226168

Valo Health Investor:
Graeme Bell
Chief Finan­cial Offi­cer
+1 – 267-3262129

Valo Health Media:
Jen­nifer Han­ley
Vice Pres­i­dent & Head of Cor­po­rate Com­mu­ni­ca­tions